Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SBB on its offer for Hemfosa
Mandate

Vinge advises SBB on its offer for Hemfosa

November 15, 2019 Capital Markets and Public M&A

Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) has announced a recommended public offer to the shareholders of Hemfosa Fastigheter AB (publ) (“Hemfosa”) to tender all their shares in Hemfosa to SBB.

The total offer consideration consists of a combination of cash and SBB shares. At announcement, the total offer value for all Hemfosa shares is approximately SEK 23.5 billion. SBB is a major Nordic social infrastructure property company with a property portfolio with a market value of SEK 30.8 billion as of 30 September 2019. SBB’s Class B and Class D common shares are listed in Nasdaq Stockholm, Large Cap.

SBB has retained Vinge as legal advisor. The Vinge team mainly consist of Jesper Schönbeck, Erik Sjöman, Rikard Lindahl, Malte Hedlund, Boris Kotur and Clara Sohlberg, and Albert Wållgren, Ludvig Wettergren and Axel Jansson (on finance matters), Trine Osen Bergqvist and Johan Wahlbom (on competition matters) and Maria Schultzberg and Victor Ericsson (on tax matters).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025